Key result
Daratumumab linked to ~6-point lower 1-year mortality in cardiac AL amyloidosis.
Why the study?
This study aimed to gain insights into real-world mortality and hospitalization among newly diagnosed patients with light chain (AL) amyloidosis with cardiomyopathy initiating anti-plasma cell dyscrasia treatment.
What are the real-world 1-year mortality and condition-related hospitalization rates by anti-plasma cell dyscrasia treatment patterns and organ involvement in newly diagnosed patients with cardiac light chain amyloidosis?
Observational (n=198)
What are the real-world 1-year mortality and condition-related hospitalization rates by anti-plasma cell dyscrasia treatment patterns and organ involvement in newly diagnosed patients with cardiac light chain amyloidosis?
In a real-world US cohort of patients with cardiac AL amyloidosis, 1-year condition-related hospitalizations were high (65.7%), with higher mortality and hospitalization rates observed among patients with concomitant renal involvement and lower mortality among those prescribed daratumumab.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for daratumumab benefit in cardiac AL amyloidosis; prospective RCTs needed before practice change.
Aim: To gain insights into real-world mortality and hospitalization among newly diagnosed patients with light chain (AL) amyloidosis initiating anti-plasma cell dyscrasia treatment. Materials & methods: This retrospective, noninterventional, observational study evaluated real-world mortality by treatment patterns and hospitalization among adult patients newly diagnosed with AL amyloidosis with cardiomyopathy in the US IQVIA PharMetrics claims database. Data from treatment initiation (index date) to 365 days postindex were evaluated. Patients receiving treatments for AL amyloidosis in the year prior to the index date were excluded. AL-, cardiac-, and cardiac/renal-related healthcare resource utilization were assigned using the International Classification of Diseases, Tenth Revision . Summary statistics are reported by cardiac or cardiac/renal involvement. Results: A total of 198 patients with cardiac AL amyloidosis were included in this study (mean age, 64.8 years; 70.7% male). The 1-year mortality and condition-related hospitalization rates among all patients were 9.1% (18 of 198) and 65.7% (130 of 198), respectively. Daratumumab was prescribed for 138 (69.7%) patients, with 1-year mortality and condition-related hospitalization rates of 7.2% (10 of 138) and 67.4% (93 of 138), respectively. Daratumumab was not prescribed for 60 (30.3%) patients, with 1-year mortality and condition-related hospitalization rates of 13.3% (8 of 60) and 61.7% (37 of 60), respectively. One-year mortality and condition-related hospitalization rates among patients with only cardiac involvement (n = 66) were 7.6% (5 of 66) and 45.5% (30 of 66), respectively, and 9.8% (13 of 132) and 75.8% (100 of 132), respectively, among patients with cardiac and renal involvement (n = 132). Conclusion: Treatment patterns varied considerably among patients with AL amyloidosis. Mortality and hospitalizations were higher among patients with both cardiac and renal involvement than among those with only cardiac involvement.
No takes yet. Share an insight, caveat, or question.
Thompson et al. (2026) conducted an observational in Cardiac light chain (AL) amyloidosis (n=198). Daratumumab-based anti-plasma cell dyscrasia treatment vs. Non-daratumumab anti-plasma cell dyscrasia treatment was evaluated on 1-year mortality. Daratumumab prescription in cardiac AL amyloidosis was associated with a 7.2% 1-year mortality rate and 67.4% hospitalization rate, compared to 13.3% and 61.7% without daratumumab.
Synapse has enriched 10 related papers. Consider them for comparative context: